Pharma
Therapeutic Focus Print PDF

Oncology

A major public health issue, a priority for aging populations, a brutal impact on cancer patients and their relatives despite real advances in care and support : all are good  reasons for Hybrigenics Pharma to try to contribute both scientifically and with new therapeutics.

 

Hybrigenics starts phase 2 trial, Inecalcitol-CT2 , in hormone-refractory prostate cancer .

The first patient has been treated in France on November 7, 2007 at the European Hospital Georges Pompidou in Paris.
© 2008 hybrigenics